Evidence map›Paper›PMID 37066156›Full record

ArticlebioRxiv : the preprint server for biology2023

Formulation development and comparability studies with an aluminum-salt adjuvanted SARS-CoV-2 Spike ferritin nanoparticle vaccine antigen produced from two different cell lines.

Ozan S Kumru, Mrinmoy Sanyal, Natalia Friedland, John Hickey, Richa Joshi, Payton Weidenbacher, Jonathan Do, Ya-Chen Cheng, Peter S Kim, Sangeeta B Joshi and 1 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 4 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Ozan S KumruDepartment of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA.
Mrinmoy SanyalDepartment of Biochemistry, Stanford University School of Medicine, Palo Alto, CA, 94305 USA.
Natalia FriedlandDepartment of Biochemistry, Stanford University School of Medicine, Palo Alto, CA, 94305 USA.
John HickeyDepartment of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA.
Richa JoshiDepartment of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA.
Payton WeidenbacherDepartment of Biochemistry, Stanford University School of Medicine, Palo Alto, CA, 94305 USA.
Jonathan DoDepartment of Biochemistry, Stanford University School of Medicine, Palo Alto, CA, 94305 USA.
Ya-Chen ChengDepartment of Biochemistry, Stanford University School of Medicine, Palo Alto, CA, 94305 USA.
Peter S KimDepartment of Biochemistry, Stanford University School of Medicine, Palo Alto, CA, 94305 USA.
Sangeeta B JoshiDepartment of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA.
David B VolkinDepartment of Pharmaceutical Chemistry, Vaccine Analytics and Formulation Center, University of Kansas, Lawrence, KS 66047, USA.
Stanford University · USUniversity of Kansas · USChan Zuckerberg Initiative (United States) · US

Funding

Creating high-resolution, epitope-focused vaccinesDP1AI158125 · NIAID · STANFORD UNIVERSITY · PI KIM, PETER S · 2020 to 2024
$5.9M
NIAID NIH HHS DP1 AI158125
6 · The paper itself

Abstract

The development of safe and effective second-generation COVID-19 vaccines to improve affordability and storage stability requirements remains a high priority to expand global coverage. In this report, we describe formulation development and comparability studies with a self-assembled SARS-CoV-2 spike ferritin nanoparticle vaccine antigen (called DCFHP), when produced in two different cell lines and formulated with an aluminum-salt adjuvant (Alhydrogel, AH). Varying levels of phosphate buffer altered the extent and strength of antigen-adjuvant interactions, and these formulations were evaluated for their (1)

Identifiers

PMID37066156
PMCPMC10103975
OpenAlexW4362638981

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.